Wyss Zürich Logo with claim Wyss Zürich Anniversary Logo
All News

ATLyphe Therapeutics AG wins Venture Kick's second stage support

17-09-2021 – ATLyphe Therapeutics AG win the Venture Kick's second stage of financial and entrepreneurial support. This support will help the project advance its development of an antibody-enabled blood stem cell transplantation treatment against Acute Myeloid Leukemia.

Wysszurich keyvisual phire

The team behind ATLyphe Therapeutics AG found itself during a 4-year long collaborative effort between ETH Zurich and University Hospital Zurich. They are developing a novel immunologic approach to selectively eliminate the patient’s healthy and diseased hematopoietic cells and therefore enable HSCT and potential cure. The funds from Venture Kick will be used for Business Development and IP-related experiments.

Similar News

MUVON at the IFAS Innovation Challenge 2021 ©Cosanum 27-09-2021

MUVON wins second place at IFAS Innovation Challenge 2021

MUVON Therapeutics was selected as one of twelve finalists for 2021's IFAS Innovation Challenge and places second in the final pitching round.
Wysszurich keyvisual seervision 19-10-2021

Seervision AG raises 3.7M CHF to accelerate market expansion

Seervision AG has successfully completed a financing round to build upon its sales channel partnerships and help companies professionalize their hybrid event presence in a wide range of use cases.
Wysszurich keyvisual hylomorph 03-12-2021

HYLOMORPH AG successfully raises 5.2M CHF during Series-B round

HYLOMORPH AG, a Wyss Zurich alumni and rapidly growing clinical-stage medtech startup with a history of national and international recognition, completed a CHF 5.2 million Series-B financing round....